Handelsbanken Fonder Ab Regenxbio Inc. Transaction History

Handelsbanken Fonder Ab

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 03, 2022	SELL	$19.35 - $35.04 $17,415 - $31,536	-900 Reduced 9.68%	8,400 $207,000
Q2 2021 Aug 03, 2021	BUY	$32.46 - $40.48 $71,412 - $89,056	2,200 Added 30.99%	9,300 $361,000
Q4 2020 Feb 11, 2021	BUY	$26.52 - $49.35 $188,292 - $350,385	7,100 New	7,100 $322,000
Q3 2020 Nov 13, 2020	SELL	$27.01 - $40.26 $191,771 - $285,846	-7,100 Closed	0 $0
Q2 2020 Aug 13, 2020	BUY	$27.75 - $43.44 $197,025 - $308,424	7,100 New	7,100 $261,000

193

43.5M

58.9K

58.4K

Ticker RGNX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,230,000
Market Cap $404M
Description
REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprie...

Get notified when there are updates to the investment portfolio of Handelsbanken Fonder Ab, based on Form 13F filings with the SEC.

Stay updated on Handelsbanken Fonder Ab with notifications on news.